BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. J Viral Hepat 2018;25:4-9. [DOI: 10.1111/jvh.12807] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kharazmi-Khorassani J, Asoodeh A. Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549). Environ Toxicol 2019;34:941-9. [PMID: 31067016 DOI: 10.1002/tox.22765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Peng D, Xing HY, Li C, Wang XF, Hou M, Li B, Chen JH. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:348. [PMID: 33076834 DOI: 10.1186/s12876-020-01477-8] [Reference Citation Analysis]
3 Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, Liu Y, Chen L, Li M, Wang G, Yuan Z, Diao B, Wu Y, Chen Y. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis 2020;71:2150-7. [PMID: 32442287 DOI: 10.1093/cid/ciaa630] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
4 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Liu J, Shen Y, Wen Z, Xu Q, Wu Z, Feng H, Li Z, Dong X, Huang S, Guo J, Zhang L, Chen Y, Li W, Zhu W, Du H, Liu Y, Wang T, Chen L, Teboul JL, Annane D, Chen D. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study. Front Immunol 2021;12:673693. [PMID: 34408744 DOI: 10.3389/fimmu.2021.673693] [Reference Citation Analysis]
6 Tillmann HL, Samuel G. Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opin Pharmacother 2019;20:873-85. [PMID: 30857443 DOI: 10.1080/14656566.2019.1583744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu X, Liu Y, Wang L, Hu L, Liu D, Li J. Analysis of the prophylactic effect of thymosin drugs on COVID-19 for 435 medical staff: A hospital-based retrospective study. J Med Virol 2021;93:1573-80. [PMID: 32897543 DOI: 10.1002/jmv.26492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
9 Bassit L, Ono SK, Schinazi RF. Moving Fast Toward Hepatitis B Virus Elimination. Adv Exp Med Biol 2021;1322:115-38. [PMID: 34258739 DOI: 10.1007/978-981-16-0267-2_5] [Reference Citation Analysis]
10 Wu X, Shi Y, Zhou J, Sun Y, Piao H, Jiang W, Ma A, Chen Y, Xu M, Xie W, Cheng J, Xie S, Shang J, Cheng J, Xie Q, Ding H, Zhang X, Bai L, Zhang M, Wang B, Chen S, Ma H, Ou X, Jia J, You H. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther 2018;18:61-9. [PMID: 30063860 DOI: 10.1080/14712598.2018.1451511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
11 Yang X, Chen Y, Zhang J, Tang T, Kong Y, Ye F, Zhang X, Liu X, Lin S. Thymosin α1 treatment reduces hepatic inflammation and inhibits hepatocyte apoptosis in rats with acute liver failure. Exp Ther Med 2018;15:3231-8. [PMID: 29545840 DOI: 10.3892/etm.2018.5843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Pica F, Gaziano R, Casalinuovo IA, Moroni G, Buè C, Limongi D, D'Agostini C, Tomino C, Perricone R, Palamara AT, Sinibaldi Vallebona P, Garaci E. Serum thymosin alpha 1 levels in normal and pathological conditions. Expert Opin Biol Ther 2018;18:13-21. [PMID: 30063864 DOI: 10.1080/14712598.2018.1474197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Matteucci C, Argaw-Denboba A, Balestrieri E, Giovinazzo A, Miele M, D'Agostini C, Pica F, Grelli S, Paci M, Mastino A, Sinibaldi Vallebona P, Garaci E, Tomino C. Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases. Expert Opin Biol Ther 2018;18:23-31. [PMID: 30063863 DOI: 10.1080/14712598.2018.1474198] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]